Abstract 140P
Background
Periampullary carcinoma accounts for over 30,000 cancer-related deaths per year in the US. The outcome of the disease differs according to the chosen modality of treatment. This study compared the survival rate between patients undergoing pancreaticoduodenectomy alone versus those receiving neoadjuvant chemotherapy before undergoing the surgery in stage II and III periampullary carcinoma.
Methods
Using the SEER database, we extracted the data of 868 patients with periampullary carcinoma from 2007 to 2011, aged between 40-79 years old. We selected patients with periampullary carcinomas who underwent pancreaticoduodenectomy alone compared to those received neoadjuvant chemotherapy before the surgery.
Results
The highest 5-year survival rate was observed in patients receiving neoadjuvant chemotherapy followed by pancreaticoduodenectomy (20.1%); especially those of stage II (20.1%). However, we found no significant difference in overall survival regarding the patients' gender or race.Table:
140P
| Variables | Overall survival | p-value |
|---|---|---|
| Therapy Surgery Combined | 17.3% 20.1% | 0.000** |
| Stage II III | 20.1% 7.9 % | 0.000** |
| Race White Black | 19.0% 22.7% | 0.732 |
| Sex Male Female | 19.3% 19.5% | 0.388 |
Highly significant p-value at ≤ 0.001 Combined: neoadjuvant chemotherapy and surgery.
Conclusions
Patients receiving neoadjuvant chemotherapy before pancreaticoduodenectomy had better 5-year overall survival compared to those undergoing pancreaticoduodenectomy alone; especially stage II.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Mai Abdelkader.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
117P - Short-term and long-term outcomes of hepatectomy combined with intraoperative radiofrequency ablation for multiple colorectal liver metastases: A propensity score matching study
Presenter: Wenbai Huang
Session: Poster display session
Resources:
Abstract
119P - The impacts of dose-time-fractionation schedules on pathological complete response rate (pCR) and local recurrence (LR)
Presenter: Fu Jin
Session: Poster display session
Resources:
Abstract
120P - Platelet to lymphocyte ratio is associated with tumour localization and outcomes in patients with metastatic colorectal cancer
Presenter: Ahmet Bilici
Session: Poster display session
Resources:
Abstract
121P - Meta-analysis of three-dimensional versus two-dimensional laparoscopic surgery for rectal cancer
Presenter: Laiyuan Li
Session: Poster display session
Resources:
Abstract
127P - Outcomes based on albumin‐bilirubin (ALBI) grade in the phase III CELESTIAL trial of cabozantinib versus placebo in patients with advanced hepatocellular carcinoma (HCC)
Presenter: Stephen Chan
Session: Poster display session
Resources:
Abstract
128P - Tislelizumab in combination with chemotherapy for Chinese patients (Pts) with gastric/gastroesophageal junction cancer (GC/GEJC) or esophageal squamous cell carcinoma (ESCC)
Presenter: Yuxian Bai
Session: Poster display session
Resources:
Abstract
129P - Monitoring patient-specific mutation in ctDNA and CTC for tumour response evaluation after neoadjuvant chemotherapy in advanced gastric adenocarcinoma (NCT03425058)
Presenter: Tao Fu
Session: Poster display session
Resources:
Abstract
130P - Development of a liver cancer risk prediction model for the general population in china: A potential tool for screening
Presenter: Xiaoshuang Feng
Session: Poster display session
Resources:
Abstract
131P - Cabozantinib in Asian patients with hepatocellular carcinoma and other solid tumours: Population pharmacokinetics analysis
Presenter: Chih-Hung Hsu
Session: Poster display session
Resources:
Abstract
132P - Liposomal irinotecan (nal-IRI) plus 5-fluorouracil/levoleucovorin (5 FU/LV) vs 5-FU/LV in Japanese patients (pts) with gemcitabine-refractory metastatic pancreatic cancer (mPAC)
Presenter: Tatsuya Ioka
Session: Poster display session
Resources:
Abstract